SUCCESS RATES
OF ONCOLYTIC VIRUS THERAPY
The OPTiM overall durable response rate of 16.3% describes a heterogeneous population mixing stages IIIB through IVM1c.
T-VEC Efficacy Numbers
- 16.3%OPTiM overall durable response rateHeterogeneous population — not stage-specific.
- 62%ORR: T-VEC + pembrolizumab (Phase Ib/II)First-line checkpoint inhibitor-naive unresectable melanoma.
- 10+ yrsDuration of some ongoing complete responsesOPTiM long-term follow-up data.
Why the Overall Number Is Almost Useless for Individual Patients
The 16.3% OPTiM durable response rate describes the average of a population that mixed stage IIIB patients with decade-long survival potential and stage IVM1c patients with visceral disease and fundamentally different biology. It does not describe any individual in it.
“Ask for the number that describes your situation — specifically your disease stage. Not the aggregate.”
Response Data by Disease Stage
OPTiM Overall Population
Stage IIIB–IVM1a Subgroup
T-VEC + Pembrolizumab (MASTERKEY Phase Ib/II)
PVSRIPO — Recurrent GBM (Phase Ib)
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About T-VEC Response Rates for Your Stage?
CancerFax reviews your staging and treatment history to provide context-specific information about expected outcomes at specialist centres.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.